Takeda Pharmaceutical To Release Sustained-Release Morphine Hydrochloride Capsule
Main Category: Cancer / OncologyAlso Included In: Pain / Anesthetics
Article Date: 17 Apr 2006 - 0:00 PDT
| Patient / Public: | ![]() |
1 (1 votes) |
| Healthcare Prof: | ![]() |
Tokyo, April, 2006 (JCN) - Takeda Pharmaceutical has launched Passif, its proprietary sustained release capsule of morphine hydrochloride.
Available in three dosages 30mg, 60mg and 120mg, the new agent is indicated for the treatment of pain control for cancer patients with moderate to severe pain. It can exert beneficial effects with a once-a-day dosage.
By Aki Tsukioka, JCN Staff Writer
Company Profile
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
Visit our cancer / oncology section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/41691.php>
APA
http://www.medicalnewstoday.com/releases/41691.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





